Brind.

Small-Cap Healthcare Comparison: Oramed Pharmaceuticals vs. BeyondSpring

1 report, 1 independent Updated Nov 9
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Oramed Pharmaceuticals Inc. and BeyondSpring were classified as small-cap healthcare companies. A comparison of the two firms showed that Oramed Pharmaceuticals has higher revenue and earnings than BeyondSpring. BeyondSpring is currently trading at a lower price-to-earnings ratio and has a significantly lower volatility compared to Oramed Pharmaceuticals.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differences in risk and valuation between the two small-cap firms. Oramed Pharmaceuticals has a beta of 1.31, indicating higher volatility, while BeyondSpring has a beta of -0.12. BeyondSpring also reports a higher percentage of institutional ownership at 40.3% compared to Oramed Pharmaceuticals' 12.7% of institutional ownership.

From themarketsdaily.com

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Investment decisions in the small-cap healthcare sector might be influenced by the reported differences in valuation and risk.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped